Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com Contacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... , May 3, 2016 Intec ... a clinical-stage biopharmaceutical company, today announced the appointment of ... Regulatory Affairs. "Ms. Strauss-Levy has 15 years ... has established an outstanding track record, having supported the ... regulatory approval processes in the United States ...
(Date:5/3/2016)... Global and Chinese Surgical ... overview of the industry that covers definition, applications ... report explores into the international and Chinese players ... Surgical Mesh market spread across 150 pages providing ... is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html . ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... ... 05, 2016 , ... Derrin Doty Group has unveiled the latest charity campaign ... communities west of Seattle. The insurance provider’s caring team has been so moved by ... due to complications from the flu, that they have decided to extend their original ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of ... to host the 2016 National SACA Leadership Conference on the Portland campus September ... chapter officers to come together and develop skills to be future leaders in ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Vitenas Cosmetic Surgery ... Design Awards, presented by the American Institute of Architects and the Academy of Architecture ... the renowned Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, ... double board certified and the only facial plastic surgeon in Atlanta to offer ... such as stem cells can be used to provide stabilization to hair transplant results ...
Breaking Medicine News(10 mins):